ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
Dow Jones
38.675,68
1,18%
Euro vs US Dollar
1,07735
0,00%
Bitcoin
62.912,69
0,04%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Innoviva Inc (INVA)

  7. Innoviva Inc (INVA) News

INVA

Innoviva (INVA)

Innoviva Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:INVA
DatumZeitQuelleÜberschriftSymbolFirma
24/04/202413h00Business WireInnoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024NASDAQ:INVAInnoviva Inc
08/03/202401h04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INVAInnoviva Inc
08/03/202401h02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INVAInnoviva Inc
08/03/202401h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INVAInnoviva Inc
08/03/202400h57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INVAInnoviva Inc
29/02/202423h01Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:INVAInnoviva Inc
29/02/202422h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INVAInnoviva Inc
29/02/202422h05Business WireInnoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company ProgressNASDAQ:INVAInnoviva Inc
23/02/202403h31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INVAInnoviva Inc
23/02/202403h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INVAInnoviva Inc
14/02/202413h23Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:INVAInnoviva Inc
23/01/202403h16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INVAInnoviva Inc
22/01/202420h03Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:INVAInnoviva Inc
11/01/202402h26Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:INVAInnoviva Inc
17/11/202322h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INVAInnoviva Inc
06/11/202314h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INVAInnoviva Inc
01/11/202321h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INVAInnoviva Inc
01/11/202321h15Business WireInnoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:INVAInnoviva Inc
01/11/202321h05Business WirePositive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated GonorrheaNASDAQ:INVAInnoviva Inc
19/09/202314h30Business WireInnoviva to Participate in the Cantor Global Healthcare ConferenceNASDAQ:INVAInnoviva Inc
18/09/202314h00Business WireXACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in AdultsNASDAQ:INVAInnoviva Inc
01/09/202302h12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INVAInnoviva Inc
01/09/202302h12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INVAInnoviva Inc
01/09/202302h12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INVAInnoviva Inc
01/09/202302h10Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:INVAInnoviva Inc
01/09/202302h10Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:INVAInnoviva Inc
01/09/202302h10Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:INVAInnoviva Inc
31/08/202319h58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INVAInnoviva Inc
25/08/202323h24Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INVAInnoviva Inc
25/08/202322h52Business WireInnoviva Appoints Stephen Basso as Chief Financial OfficerNASDAQ:INVAInnoviva Inc
 Showing the most relevant articles for your search:NASDAQ:INVA

Kürzlich von Ihnen besucht

TG
CBK
Commerzbank
TG
LHA
Deutsche Lufthansa
COIN
BTCUSD
Bitcoin
PM
XAUUSD
Gold vs US Dollar
TG
BAYN
Bayer
USOTC
BNPQY
BNP Paribas (QX)
NASDAQ
QQQ
Invesco QQQ Trust Series 1
FX
EURGBP
Euro vs Sterling
USOTC
RHHBY
Roche (QX)
DBI
TDXP
Tec DAX
NASDAQ
AMZN
Amazon.com
FX
EURJPY
Euro vs Yen
TG
BAS
BASF
NYSE
XOM
Exxon Mobil
CCOM
US100
US Tech 100
NYSE
NKE
Nike
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten